

Ref: FOI/GS/ID 8639

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

16 November 2023

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Gastric Oesophageal cancer and Ovarian cancer.

You asked:

Q1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:

- a. CAPOX (Capecitabine with Oxaliplatin)*
- b. FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)*
- c. Lonsurf (Trifluridine - tipiracil)*
- d. Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)*
- e. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)*
- f. Any other systemic anti-cancer therapy*
- g. Palliative care only*

Q2. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:

- a. Nivolumab monotherapy or combination with Ipilimumab*
- b. Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)*
- c. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)*
- d. Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)*
- e. Any other systemic anti-cancer therapy*
- f. Palliative care only*

Q3. How many patients were treated in the past 3 months for ovarian cancer (any stage) with:

- a. Paclitaxel in combination with a platinum-based compound*

- b. *Platinum-based therapy alone (cisplatin or carboplatin)*
- c. *Bevacizumab in combination with paclitaxel and carboplatin*
- d. *Olaparib*
- e. *Olaparib + Bevacizumab*
- f. *Niraparib*
- g. *Rucaparib*

Q4. If data for HRD (homologous recombination deficiency) testing is available, please provide how many HRD positive ovarian cancer patients were treated in the last 3 months with:

- a. *Olaparib*
- b. *Olaparib + Bevacizumab*
- c. *Niraparib*
- d. *Other treatments*

Q5. Does your trust participate in any clinical trials for the treatment of ovarian cancer? If so, please provide the name of each trial along with the number of patients taking part.

Trust response:

Q1.

- a. 6
- b. 1
- c. 0
- d. 1
- e. 0
- f. 23
- g. 1

Q2.

- a. 1
- b. 0
- c. 2
- d. 36
- e. 15
- f. 8

Q3.

- a. 21
- b. 13
- c. 4
- d. 7
- e. 7
- f. 9
- g. 7

Q4. This information is not held in a reportable format on either of our oncology systems. The Trust has estimated that it will cost more than the appropriate limit to consider your request. The appropriate limit is specified in regulations and represents the estimated cost of one person spending 3½ working days in determining whether the Trust holds the information, locating, retrieving and extracting the information. Under Section 12 of the Freedom of Information Act 2000 the Trust is not obliged to comply with your request and we will not be processing your request further.

Q5. PROTECTOR (Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal) IRAS 237992 - 6 patients recruited